RBC Capital analyst Gregory Renza maintained a Hold rating on Fulcrum Therapeutics (FULC – Research Report) yesterday and set a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback